Evolution of pulmonary embolism: 1 year of follow-up Source: Eur Respir J 2006; 28: Suppl. 50, 401s Year: 2006
Should oral anticoagulation be discontinued after 3 months in the setting of a first high-risk pulmonary embolism secondary to a major transient/reversible risk factor? Source: Eur Respir J, 55 (1) 1902028; 10.1183/13993003.02028-2019 Year: 2020
Should oral anticoagulation be discontinued after 3 months in the setting of a first high-risk pulmonary embolism secondary to a major transient/reversible risk factor? Source: Eur Respir J, 55 (1) 1902323; 10.1183/13993003.02323-2019 Year: 2020
Risk factors for recurrences in patients with idiopathic pulmonary embolism after withdrawal of long-term anticoagulation Source: Eur Respir J 2006; 28: Suppl. 50, 44s Year: 2006
Different mortality, recurrence and bleeding between cancer and non cancer patients with pulmonary embolism (PE): 1 year follow-up. Source: International Congress 2017 – Prognostic factors and outcomes in pulmonary embolism Year: 2017
Early discharge of patients with pulmonary embolism: feasibility of domicillary anticoagulation Source: Eur Respir J 2003; 22: Suppl. 45, 219s Year: 2003
Impact of two 5-year anticoagulant strategies on survival and echocardiographic parameters in the patients with chronic thromboembolic pulmonary hypertension (CTEPH) who did not undergo pulmonary endarterectomy Source: Annual Congress 2004 - Pulmonary embolism Year: 2004
Outcome during and after anticoagulant therapy in cancer patients with incidentally found pulmonary embolism Source: Eur Respir J 2016; 48: 1360-1368 Year: 2016
Recurrence and bleeding in the extended treatment of patients with pulmonary embolism (PE) and cancer Source: International Congress 2018 – Diagnosis, prognostication and treatment of pulmonary embolism Year: 2018
Oral anticoagulation therapy in pediatric pulmonary hypertension: A 10-year registry survival analysis Source: Annual Congress 2010 - Pulmonary circulation: clinical aspects Year: 2010
Complications of anticoagulant therapy in patients with pulmonary thromboembolism Source: Eur Respir J 2007; 30: Suppl. 51, 604s Year: 2007
Analysis of long-term survival of patients diagnosed of pulmonary embolism (PE) Source: Annual Congress 2006 - Pulmonary embolism Year: 2006
The outcome of anticoagulation alone therapy for patients with submassive pulmonary embolism Source: International Congress 2019 – Epidemiology and management of acute pulmonary embolism Year: 2019
Clinical profile and mortality of patients with pulmonary embolism and cancer Source: International Congress 2015 – Pulmonary circulation: the story of fresh and old clots Year: 2015
Evaluation of the PADIS score stratifying risk for venous thromboembolism recurrence after a first unprovoked pulmonary embolism: results from the REVERSE study Source: Eur Respir J, 59 (2) 2101801; 10.1183/13993003.01801-2021 Year: 2022
Pulmonary sequelae in patients with COVID-19: results after 3 months of follow-up Source: Virtual Congress 2021 – Interstitial lung disease, COVID-19 and friends Year: 2021
Prevalence of chronic thromboembolic pulmonary hypertension 2 years after pulmonary embolism Source: Annual Congress 2008 - Pulmonary venous thromboembolic disease Year: 2008
Longterm survival of inoperable chronic thromboembolic pulmonary hypertension (CTEPH) Source: Annual Congress 2008 - Acute and chronic pulmonary thromboembolic disease Year: 2008
Efficacy of age adjusted d-dimer in excluding pulmonary embolism in patients with cancer. Source: Virtual Congress 2020 – Epidemiology, diagnosis and management of pulmonary embolism Year: 2020
Effect of statin therapy in patients with lung cancer on mortality, incidence of infections and pulmonary embolism Source: Annual Congress 2012 - Screening, diagnosis, staging and treatment strategies for lung cancer Year: 2012